PAPER Emre M, Tsolaki M, Bonuccelli U, Destée A, Tolosa E, Kutzelnigg A, Ceballos-Baumann A, Zdravkovic S, Bladström A, Jones R,

Memantine for patients with Parkinson's disease dementia or dementia with Lewy bodies: a randomised, double-blind, placebo-controlled trial.

Lancet Neurol. 2010 Oct;9(10):969-77. PubMed: 20729148

PAPER Ringman JM, Medina LD, Braskie M, Rodriguez-Agudelo Y, Geschwind DH, Macias-Islas MA, Cummings JL, Bookheimer S

Effects of risk genes on BOLD activation in presymptomatic carriers of familial Alzheimer's disease mutations during a novelty encoding task.

Cereb Cortex. 2011 Apr;21(4):877-83. PubMed: 20729396

PAPER Sahara N, Lewis J

Amyloid precursor protein and tau transgenic models of Alzheimer's disease: insights from the past and directions for the future.

Future Neurol. 2010 May 1;5(3):411-420. PubMed: 20730022

PAPER Cruz NF, Ball KK, Dienel GA

Astrocytic gap junctional communication is reduced in amyloid-β-treated cultured astrocytes, but not in Alzheimer's disease transgenic mice.

ASN Neuro. 2010;2(4):e00041. PubMed: 20730033

PAPER Suo WZ, Li L

Dysfunction of G protein-coupled receptor kinases in Alzheimer's disease.

ScientificWorldJournal. 2010;10:1667-78. PubMed: 20730384

PAPER Jomova K, Vondrakova D, Lawson M, Valko M

Metals, oxidative stress and neurodegenerative disorders.

Mol Cell Biochem. 2010 Dec;345(1-2):91-104. PubMed: 20730621

PAPER Silverstein NM, Sherman R

Taking control of Alzheimer's disease: a training evaluation.

Gerontol Geriatr Educ. 2010;31(3):274-88. PubMed: 20730653

PAPER Canan F, Ataoglu A

Memantine-related psychotic symptoms in a patient with bipolar disorder.

J Clin Psychiatry. 2010 Jul;71(7):957. PubMed: 20667296

PAPER Wong KK, Muller ML, Kuwabara H, Studenski SA, Bohnen NI

Olfactory loss and nigrostriatal dopaminergic denervation in the elderly.

Neurosci Lett. 2010 Nov 5;484(3):163-7. PubMed: 20727944

PAPER Wang XH, Li L, Hölscher C, Pan YF, Chen XR, Qi JS

Val8-glucagon-like peptide-1 protects against Aβ1-40-induced impairment of hippocampal late-phase long-term potentiation and spatial learning in rats.

Neuroscience. 2010 Nov 10;170(4):1239-48. PubMed: 20727946

Lon S. Schneider on Lilly Halts IDENTITY Trials as Patients Worsen on Secretase Inhibitor

COMMENT Semagacestat continues the streak of late-phase trial failures. All failed for lack of efficacy, but as enzyme inhibitors and antibodies are advanced, serious toxicity in the trials may become more frequent as well. Sequential failures discovered late in

Ubiquitin (Ubi-1)

ANTIBODY monoclonal Ubi-1 manufacturer Cat# sc-52750 immunogen = purified ubiquitin of cow origin liquid, ascites, azide detects ubiquitin IgG₁ Posttranslational Modifications Santa Cruz Mouse Cow Human Mouse C. elegans Drosophila Ubiquitin

Ubiquitin (98.54)

ANTIBODY monoclonal 98.54 manufacturer Cat# sc-130410 immunogen = full length recombinant Ub of human origin liquid, PBS, azide, gelatin detects ubiquitin IgG_2a Posttranslational Modifications Santa Cruz Mouse Human Ubiquitin http://alzforum

Ubiquitin (6C1)

ANTIBODY monoclonal 6C1 manufacturer Cat# sc-47721 immunogen = cow erythrocyte ubiquitin liquid, azide detects ubiquitin IgG_2a Posttranslational Modifications Santa Cruz Mouse Non-specific Ubiquitin http://alzforum.org/res/com/ant/default.as

Ubiquitin (1B4-UB)

ANTIBODY monoclonal 1B4-UB manufacturer Cat# sc-58449 immunogen = Ub from cow erythrocytes conjugated to bovine gammaglobulin liquid, PBS, azide, gelatin detects ubiquitin IgG₁ Posttranslational Modifications Santa Cruz Mouse Cow Human Ubiqu